Published in final edited form as:

Bioorg Med Chem Lett. 2011 April 15; 21(8): 2400–2402. doi:10.1016/j.bmcl.2011.02.069.

6-Benzoyl-3-hydroxypyrimidine-2,4-diones as Dual Inhibitors of HIV Reverse Transcriptase and Integrase

Jing Tang^a, Kasthuraiah Maddali^b, Christine D. Dreis^a, Yuk Y. Sham^a, Robert Vince^a, Yves Pommier^b, and Zhengqiang Wang^{a,*}

^aCenter for Drug Design, Academic Health Center, University of Minnesota, 516 Delaware St SE, Minneapolis, MN 55455

^bLaboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

Abstract

N-3-Hydroxylation of pyrimidine-2,4-diones was recently found to yield inhibitors of both HIV-1 reverse transcriptase (RT) and integrase (IN). An extended series of analogues featuring a benzoyl group at the C-6 position of the pyrimidine ring was synthesized. Through biochemical studies it was found that these new analogues are dually active against both RT and IN in low micromolar range. Antiviral assays confirmed that these new inhibitors are active against HIV-1 in cell culture at nanomolar to low micromolar range, further validating 3-hydroxypyrimidine-2,4-diones as a viable scaffold for antiviral development.

Keywords

HIV; 6-Benzoyl-3-hydroxypyrimidine-2,4-diones; dual inhibitors; reverse transcriptase; integrase

Human immunodeficiency virus (HIV) infects an estimated 33 million people globally and poses a huge healthcare challenge with high mortality and morbidity rates.¹ As effective HIV vaccines remain elusive despite tremendous efforts,^{2, 3} chemotherapy continues to provide the main leverage in battling HIV / AIDS. Current standard therapy, the highly active antiretroviral therapy (HAART),^{4, 5} involves the use of multiple antivirals with orthogonal mechanisms of action to create a large genetic barrier to resistance. Its success in clinically managing HIV / AIDS notwithstanding, HAART requires nearly perfect adherence^{6, 7} which can be difficult to achieve with the complex dosing of multi-target therapy. Suboptimal compliance generally leads to treatment failure and development of multi-drug resistance.^{6, 7} Drug-drug interactions are among the most prominent complications of HAART.⁸ Simplifying HAART regimens to improve adherence has been a subject of tremendous research efforts and interests.^{9, 10} Conceptually the simplest form of multi-target therapy would be a single structure compound inhibiting multiple viral targets. We have previously reported various examples^{11–15} of single structure dual inhibitors of HIV-1 RT and IN. Of particular interest was our recently disclosed RT / IN dual inhibitor

© 2011 Elsevier Ltd. All rights reserved.

Corresponding Author Footnote To whom correspondence should be addressed. Phone: +1 (612) 626-7025; Fax: +1 (612) 625-8154. wangx472@umn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

scaffold¹⁴ based on pyrimidine-2,4-dione non-nucleoside RT inhibitors (NNRTI). In this case, N-3 hydroxylation of known 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymine (HEPT) type NNRTIs yielded new compounds active against IN while retaining inhibition against RT (Figure 1, chemotype **I**).¹⁴ Interestingly, similar to HEPT, pyrimidine-2,4-diones featuring a C-6 benzoyl group (chemotype **IIa**) also represent an important class of NNRTIs.^{16–22} It is easily conceived that introducing an N-3 hydroxy group to these NNRTIs could generate a new molecular scaffold for inhibitors of RT (RTI) and IN (INI) (Figure 1, chemotype **IIb**). Here we report the synthesis and biological evaluation of this extended series of 6-benzoyl-3-hydroxypyrimidine-2,4-diones.

The new chemotype was synthesized via a route described in Scheme 1. The synthesis involves key intermediates **7** and **8** which were prepared starting from readily available malonate **1** following reported procedures.^{16–18} The N-1 ether linkage was then introduced through a regio-selective alkylation with a chloromethyl ether to give compounds **9–16**. N-3-hydroxylation was achieved via a base-mediated *m*-CPBA oxidation¹⁴ to produce final compounds **17–24**.

Final compounds **17–24** were biochemically evaluated against recombinant HIV-1 RT and IN. For the RT assay, all compounds were first screened at two different concentrations (100 μ M and 10 μ M) and the promising ones were then assayed in dose response fashion. It was observed from these assays that except for **21** these newly synthesized analogues generally inhibit RT at low micromolar concentrations (Table 1). Notably, the 3,5-dimethyl group on the benzene ring of the C-6 substituent appears to significantly benefit RT binding (**19** vs **18**, **20** vs **17**, **24** vs **23**). The same effect was observed with the HEPT NNRTI GCA-186²³ where the dimethyl group on the C-6 benzene provides additional van der Waals interactions with the roof of the binding pocket. Meanwhile, the fluorine atom on the benzene ring of the N-1 side chain was found to hamper RT inhibition (**18** vs **17**, **19** vs **20**), and the extra carbon in the N-1 linker also conferred a substantial decrease in RT inhibition (**21** vs **18**, **22** vs **19**).

The ability of these new analogues to inhibit HIV-1 IN was assessed using a biochemical gel assay. Both the 3' processing (3'-P) and the strand transfer (ST) functions were evaluated in this assay. The results clearly demonstrate that these compounds selectively inhibit ST at low micromolar range (Table 1). Most intriguingly, IN ST inhibition seems to have a high dependence on the benzene ring in N-1 side chain as the two analogues with an aliphatic N-1 side chain (**23–24**) showed no inhibition. Another major observation was that the extra carbon on the N-1 linker appears to considerably benefit IN binding as compounds **21–22** exhibit significantly higher potency against IN. It was also found that the fluorine atom on the N-1 benzene tends to slightly favor IN inhibition (**18** vs **17**, **19** vs **20**). These findings conform to the common pharmacophore of IN ST inhibitors in which a fluorobenzyl group with a specific spatial arrangement to a chelator is a required structural determinant.^{15, 24–28}

To confirm the binding of our compounds to both RT and IN, a representative inhibitor (**20**) was docked into both the NNRTI binding pocket (A)¹⁴ and the IN catalytic core domain (CCD) (B)²⁹ using Glide v2.5 at Standard Precision.³⁰ Significantly, the N-3 OH of **20** is hydrogen bonded to the K101 backbone in the NNRTI binding pocket, allowing the inhibitor to adopt a conformation where the C-6 benzene ring interacts favorably with the Y188, and the N-1 side chain sits in an open channel (Figure 2, A). On the other hand, the same inhibitor was found to fit nicely into the IN CCD in complex with Mg²⁺ and viral DNA (Figure 2, B). The deprotonation of the N-3 OH group of the pyrimidine ring allows the chelation of two Mg²⁺ ions and the placement of the N-1 benzyl group into the protein-DNA interfacial hydrophobic pocket. These docking studies corroborate the observed dual inhibitory activities and suggest that this chemotype has the ability to engage with both RT and IN.

Finally, the antiviral activity of these new compounds was evaluated in CEM-SS cells with the IIB strain of HIV-1 using an assay based on viral cytopathic effect (CPE). The reduction of CPE was used to indicate the inhibition of viral replication. Compounds were first tested at a single concentration (10 μ M) for antiviral activity and cell viability. The active ones were then tested in dose response fashion.

As shown in table 2, except for compound **22**, all new compounds yielded 100% inhibition against HIV-1 at 10 μ M without appreciable cytotoxicity (Table 2). Further testing in dose-response fashion found that these compounds inhibit HIV-1 at low micromolar to low nanomolar range. The parallel cytotoxicity assay showed that all final compounds are generally safe with favorable therapeutic indices. Interestingly, compound **24** which inhibited RT with the highest potency in the series while lacking anti-IN activity, and compound **21** which showed the best anti-IN activity with only marginal inhibition against RT, both demonstrated excellent antiviral activity. The overall anti-HIV-1 activity of the rest of the compounds likely reflects the dual inhibitory activities against both RT and IN.

In summary, based on recently disclosed N-3-hydroxypyrimidine-2,4-diones as a new chemotype for dual inhibitors of HIV-1 RT and IN, we have synthesized an extended series of analogues featuring a benzoyl group at the C-6 position of the pyrimidine. Through biochemical studies and cell culture antiviral assays it was found that these new analogues inhibit RT, IN and HIV-1 at nanomolar to low micromolar range. Molecular modeling also suggests that these compounds can fit nicely into both the NNRTI binding pocket and IN CCD. These results provide further support on 3-hydroxypyrimidine-2,4-diones as a valid scaffold for antiviral development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Abbreviations

HIV	human immunodeficiency virus
RT	reverse transcriptase
IN	integrase
HAART	highly active antiretroviral therapy
IN	integrase
NNRTI	non-nucleoside RT inhibitor
HEPT	1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymine
3'-P	3' processing
ST	strand transfer
CCD	catalytic core domain
CPE	cytopathic effect.

Acknowledgments

This research was supported by the Center for Drug Design at the University of Minnesota, by the Center for Cancer Research, National Cancer Institute, NIH, and by an NIH-IATAP grant to YP and KM. We thank Roger Ptak at Southern Research Institute for antiviral assays and the Minnesota Supercomputing Institute for modeling resources.

References and Notes

1. UNAIDS. 2007
2. Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, Caputo A, Gavioli R, Ensoli F, Robert-Guroff M, Barnett S, Ensoli B. *Expert Opin. Emerg. Drugs*. 2007; 12:23. [PubMed: 17355212]
3. Berkley S, Bertram K, Delfraissy J-F, Draghia-Akli R, Fauci A, Hallenbeck C, Kagame MJ, Kim P, Mafubelu D, Makgoba MW, Piot P, Walport M, Warren M, Yamada T, Esparza J, Hankins C, Johnston MI, Levy Y, Romaris M, Ahmed R, Bernstein A. *Nat. Med.* 2010; 16:981. [PubMed: 20823883]
4. Yeni P. J. *Hepatol.* 2006; 44:S100. [PubMed: 16359748]
5. Piacenti FJ. *Pharmacotherapy*. 2006; 26:1111. [PubMed: 16863488]
6. Stone VE. *Clin. Infect. Diseases*. 2001; 33:865. [PubMed: 11512092]
7. Chesney M. *AIDS patient care ST*. 2003; 17:169.
8. Katende-Kyenda NL, Lubbe MS, Serfontein JHP, Truter I. *J Clin Pharm Ther.* 2008; 33:393. [PubMed: 18613857]
9. Negredo E, Bonjoch A, Clotet B. J. *Antimicrob. Chemother.* 2006; 58:235. [PubMed: 16807250]
10. Barreiro P, Garcia-Benayas T, Soriano V, Gallant J. *AIDS Rev.* 2002; 4:233. [PubMed: 12555697]
11. Wang Z, Bennett EM, Wilson DJ, Salomon C, Vince R. J. *Med. Chem.* 2007; 50:3416. [PubMed: 17608468]
12. Wang Z, Vince R. *Bioorg. Med. Chem. Lett.* 2008; 18:1293. [PubMed: 18226894]
13. Wang Z, Vince R. *Bioorg. Med. Chem.* 2008; 16:3587. [PubMed: 18314335]
14. Tang J, Maddali K, Dreis CD, Sham YY, Vince R, Pommier Y, Wang Z. *ACS Med. Chem. Lett.* 2010
15. Wang Z, Tang J, Salomon CE, Dreis CD, Vince R. *Bioorg. Med. Chem.* 2010; 18:4202. [PubMed: 20576573]
16. Buckheit RW Jr, Hartman TL, Watson KM, Kwon HS, Lee SH, Lee JW, Kang DW, Chung SG, Cho EH. *Antiviral Chem. Chemother.* 2007; 18:259.
17. Ji L, Chen F-E, De Clercq E, Balzarini J, Pannecouque C. J. *Med. Chem.* 2007; 50:1778. [PubMed: 17381078]
18. Ji L, Chen F-E, Xie B, De Clercq E, Balzarini J, Pannecouque C. *Eur. J. Med. Chem.* 2007; 42:198. [PubMed: 17095124]
19. Ji L, Chen F-E, Feng X-Q, De Clercq E, Balzarini J, Pannecouque C. *Chem. Pharm. Bull.* 2006; 54:1248. [PubMed: 16946529]
20. Mitchell ML, Son JC, Lee IY, Lee C-K, Kim HS, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Eisenberg G, Geleziunas R, Xu L, Kim CU. *Bioorg. Med. Chem. Lett.* 2010; 20:1585. [PubMed: 20137928]
21. Mitchell ML, Son JC, Guo H, Im Y, Cho EJ, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Graupe D, Rhodes G, He GX, Geleziunas R, Xu L, Kim CU. *Bioorg. Med. Chem. Lett.* 2010; 20:1589. [PubMed: 20138513]
22. Loksha YM, Pedersen EB, Loddio R, La Colla P. *Arch. Pharm.* 2009; 342:501.
23. Hopkins AL, Ren J, Tanaka H, Baba M, Okamoto M, Stuart DI, Stammers DK. *J. Med. Chem.* 1999; 42:4500. [PubMed: 10579814]
24. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD. *Proc. Nat. Acad. Sci. USA.* 2004; 101:11233. [PubMed: 15277684]
25. Mustata GI, Brigo A, Briggs JM. *Bioorg. Med. Chem. Lett.* 2004; 14:1447. [PubMed: 15006380]
26. Barreca ML, Ferro S, Rao A, De Luca L, Zappala M, Monforte A-M, Debyser Z, Witvrouw M, Chimirri A. J. *Med. Chem.* 2005; 48:7084. [PubMed: 16250669]
27. Dayam R, Sanchez T, Clement O, Shoemaker R, Sei S, Neamati N. J. *Med. Chem.* 2005; 48:111. [PubMed: 15634005]

28. De Luca L, Barreca ML, Ferro S, Iraci N, Michiels M, Christ F, Debyser Z, Witvrouw M, Chimirri A. *Bioorg. Med. Chem. Lett.* 2008; 18:2891. [PubMed: 18417342]
29. Tang J, Maddali K, Pommier Y, Sham YY, Wang Z. *Bioorg. Med. Chem. Lett.* 2010; 20:3275. [PubMed: 20457521]
30. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. *J. Med. Chem.* 2004; 47:1139.

NIH-PA Author Manuscript

Figure 2. Inhibitory modes of binding for compound **20** within A) the NNRTI binding pocket and B) the active site of IN CCD in complex with Mg^{2+} and DNA. The electrostatic potential surface of the binding pocket is shown to highlight the hydrophobic regions (white) in both enzymes.

Scheme 1.**Synthesis of compounds 17–24a**

^aReagents and conditions: a) urea, NaOMe, MeOH, reflux, 75%; b) POCl₃, dimethylaniline, 89%; c) MeONa, MeOH, 81%; d) (i) substituted phenyl acetonitrile, NaH, DMF, rt; (ii) NaH, DMF, air, 84–87%; e) HCl, MeOH, reflux, 85–93%; f) CH₃C(OTMS)=NTMS (BSA), benzyl alcohol substrate, (HCHO)_n, TMSCl, TBAI (cat.), CH₂Cl₂, rt; or (for **15–16**) BSA, chloromethyl ethyl ether, TBAI (cat.), CH₂Cl₂, rt, 74–94%; g) NaH, m-CPBA, THF, rt, 38–68%.

Table 1Biochemical assay results of compounds **17–24** against HIV-1 RT and IN.

Compd	RT			IN IC ₅₀ (μM) ^b	
	100 μM ^a	10 μM ^a	IC ₅₀ (μM) ^b	3'-P	ST ^c
17	84	61	14	>111	37 ± 6
18	78	41	23	>111	25 ± 3
19	85	68	7.6	>111	21 ± 3
20	92	79	1.0	>111	41 ± 4
21	46	4	--	>111	4.1 ± 0.2
22	74	60	10	>111	7.0 ± 0.8
23	61	37	43	>111	>111
24	94	61	0.5	>111	>111

^a % Inhibition under single concentration.^b Concentration inhibiting enzyme activity by 50%.^c Mean value ± standard deviation from three independent measurements.

Table 2Antiviral assay results of compounds **17–24** against HIV-1.

Compd	10 μ M		Dose Response		
	% CPE ^a Reduction	% Cell Viability	EC ₅₀ (μ M) ^b	CC ₅₀ (μ M) ^c	TI ^d
17	100	98	1.4	>100	>71
18	100	100	2.0	>100	>50
19	100	100	0.36	28	78
20	100	100	0.061	33	540
21	100	100	0.34	>100	290
22	56	81	--	--	--
23	100	100	2.3	94	41
24	100	100	0.030	77	2600

^a Viral cytopathic effect;^b Concentration inhibiting viral replication by 50%;^c Concentration causing 50% cell death;^d Therapeutic index, defined by CC₅₀ / EC₅₀.